Literature DB >> 15357656

Immune thrombocytopenic purpura in a patient treated with interferon alfacon-1.

D Dimitroulopoulos1, S P Dourakis, D Xinopoulos, K Tsamakidis, E Paraskevas.   

Abstract

Immune thrombocytopenic purpura is an acquired disorder characterized by severe thrombocytopenia and caused by one or more antiplatelet autoantibodies. We present a case of a 20-year-old woman referred to our Unit for chronic hepatitis C virus (HCV) infection. At week 28 of treatment with interferon (alfacon-1), undetectable HCV RNA and transaminase levels within normal limits, the patient presented with immune thrombocytopenic purpura, which was successfully treated with immunoglobulin and methylprednisolone. Despite the high doses and long life of corticosteroid treatment HCV RNA remained undetectable.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15357656     DOI: 10.1111/j.1365-2893.2004.00536.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  4 in total

1.  Interferon-alpha induced severe thrombocytopenia: a case report and review of the literature.

Authors:  Li Li; Da-Kang Han; Jun Lu
Journal:  World J Gastroenterol       Date:  2010-03-21       Impact factor: 5.742

2.  Severe immune thrombocytopenia after peg-interferon-alpha2a, ribavirin and telaprevir treatment completion: A case report and systematic review of literature.

Authors:  Rosario Arena; Paolo Cecinato; Andrea Lisotti; Federica Buonfiglioli; Claudio Calvanese; Giuseppe Grande; Marco Montagnani; Francesco Azzaroli; Giuseppe Mazzella
Journal:  World J Hepatol       Date:  2015-06-28

3.  Monoclonal antibody Rituximab for severe immune thrombocytopenia after pegylated interferon for hepatitis C infection.

Authors:  I Papakonstantinou; I Poulakidas
Journal:  Hippokratia       Date:  2014 Oct-Dec       Impact factor: 0.471

Review 4.  A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin.

Authors:  Nisha Mistry; Jonathan Shapero; Richard I Crawford
Journal:  Can J Gastroenterol       Date:  2009-10       Impact factor: 3.522

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.